002399.SZ Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 mai 2024 @ 09:04):

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally...

Stats
Dagens volum	17.45M
Gjennomsnittsvolum	6.23M
Markedsverdi	12.98B
EPS	CNY0 ( 2024-04-28 )
Neste inntjeningsdato	( CNY0 ) 2024-05-22
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-22.15
ATR14	CNY0.0130 (0.13%)

Volum Korrelasjon

Lang: -0.50 (neutral)

Kort: 0.47 (neutral)

Signal:(38.076) Neutral

Shenzhen Hepalink Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Shenzhen Hepalink Korrelasjon - Valuta/Råvare

-0.57
( weak negative )

-0.16
( neutral )

0.00
( neutral )

-0.89
( strong negative )

0.28
( neutral )

0.87
( strong )

Shenzhen Hepalink Økonomi

Annual	2023
Omsetning:	CNY5.42B
Bruttogevinst:	CNY1.68B (30.90 %)
EPS:	CNY-0.530

FY	2023
Omsetning:	CNY5.42B
Bruttogevinst:	CNY1.68B (30.90 %)
EPS:	CNY-0.530

FY	2022
Omsetning:	CNY7.16B
Bruttogevinst:	CNY2.33B (32.61 %)
EPS:	CNY0.500

FY	2021
Omsetning:	CNY6.37B
Bruttogevinst:	CNY2.03B (31.94 %)
EPS:	CNY0.164

Financial Reports:

No articles found.

Shenzhen Hepalink

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.